Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

医学 帕博西利布 耐受性 内科学 来曲唑 富维斯特朗 肿瘤科 不利影响 转移性乳腺癌 乳腺癌 癌症 三苯氧胺
作者
Komal Jhaveri,Melissa Accordino,Philippe L. Bédard,Andrés Cervantes,Valentina Gambardella,Erika Hamilton,Antoîne Italiano,Kevin Kalinsky,Ian E. Krop,Mafalda Oliveira,Peter Schmid,Cristina Saura,Nicholas C. Turner,Andréa Varga,Sravanthi Cheeti,Stephanie Hilz,Katherine E. Hutchinson,Yanling Jin,Stephanie Royer‐Joo,Ubong Peters
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (33): 3947-3956 被引量:14
标识
DOI:10.1200/jco.24.00110
摘要

PURPOSE To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in combination with palbociclib and endocrine therapy (ET), in a phase I/Ib study in patients with PIK3CA -mutated, hormone receptor–positive/human epidermal growth factor receptor 2–negative locally advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT03006172 ). METHODS Women ≥18 years of age received inavolisib, palbociclib, and letrozole (Inavo + Palbo + Letro arm) or fulvestrant (Inavo + Palbo + Fulv arm) until unacceptable toxicity or disease progression. The primary objective was to evaluate safety or tolerability. RESULTS Fifty-three patients were included, 33 in the Inavo + Palbo + Letro arm and 20 in the Inavo + Palbo + Fulv arm. Median duration of inavolisib treatment was 15.7 and 20.8 months (cutoff: March 27, 2023), respectively. Treatment-related adverse events (TRAEs) occurred in all patients; the most frequent were stomatitis, hyperglycemia, and diarrhea; grade ≥3 any TRAE rates were 87.9% and 85.0%; 6.1% and 10.0% discontinued any treatment due to TRAEs in the Inavo + Palbo + Letro and Inavo + Palbo + Fulv arms, respectively. No PK drug–drug interactions (DDIs) were observed among the study treatments when administered. Confirmed objective response rates were 52.0% and 40.0% in patients with measurable disease, and median progression-free survival was 23.3 and 35.0 months in the Inavo + Palbo + Letro and Inavo + Palbo + Fulv arms, respectively. Available paired pre- and on-treatment tumor tissue and circulating tumor DNA analyses confirmed the effects of study treatment on pharmacodynamic and pathophysiologic biomarkers of response. CONCLUSION Inavolisib plus palbociclib and ET demonstrated a manageable safety profile, lack of DDIs, and promising preliminary antitumor activity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jasper的应助被开朗的语风采纳,获得10
刚刚
1秒前
欢蛋发布了新的文献求助10
1秒前
molihuakai的应助被李hy采纳,获得10
1秒前
Lufy完成签到,获得积分10
1秒前
2秒前
阿飞发布了新的文献求助10
2秒前
刘一完成签到 ,获得积分10
2秒前
wly发布了新的文献求助10
2秒前
2秒前
酷波er的应助被天天采纳,获得10
2秒前
可不可以发布了新的文献求助10
2秒前
山山而川完成签到,获得积分20
3秒前
3秒前
DW的应助被少国采纳,获得10
3秒前
3秒前
3秒前
122发布了新的文献求助10
3秒前
万能图书馆的应助被Heart采纳,获得10
3秒前
123qwe发布了新的文献求助20
3秒前
沐光而行完成签到,获得积分10
4秒前
Lufy发布了新的文献求助10
4秒前
syvshc的应助被liqianniu采纳,获得10
4秒前
4秒前
贪玩笑容发布了新的文献求助10
4秒前
COCKOOR完成签到,获得积分10
4秒前
4秒前
共享精神的应助被ButtcherFly采纳,获得10
5秒前
bjcyqz完成签到,获得积分10
6秒前
东起欧发布了新的文献求助10
6秒前
hehe完成签到,获得积分10
6秒前
lit发布了新的文献求助30
6秒前
6秒前
yu完成签到,获得积分10
6秒前
理塘王完成签到 ,获得积分10
6秒前
冬至发布了新的文献求助10
6秒前
善良的访冬完成签到,获得积分10
7秒前
7秒前
zxy的应助被瘦瘦毛豆采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174559
求助须知:如何正确求助?哪些是违规求助? 9566586
关于积分的说明 21787112
捐赠科研通 7768831
什么是DOI,文献DOI怎么找? 3431746
关于科研通互助平台的介绍 2555956
邀请新用户注册赠送积分活动 2477100